30 results about "Cell transplantation" patented technology

The invention discloses a method for inducing fibroblasts to be reprogrammed into mesenchymal matrix-like cells (MLCs) by using small chemical molecules and application of the mesenchymal matrix-like cells (MLCs) in the anti-aging field. The invention discloses a set of specific chemical small molecule composition and an induction scheme thereof, which can be used for efficiently reprogramming fibroblasts from somatic cells into MLCs. Furthermore, the huge potential of the MLCs obtained by the method in anti-aging research is deeply explored, and the effect of the MLCs is proved to be obviously superior to that of umbilical cord mesenchymal stem cells in the aspects of reversing cell aging phenotypes and recovering tissue functions. The invention not only provides a new stem cell source strategy for avoiding the ethical and safety problems of the traditional reprogramming technology, but also lays a solid cell foundation for developing a novel, safe and effective anti-aging therapy based on cell transplantation or secreted factors.

Described herein, inter alia, are compositions and methods of use for administering a population of regulatory T (TREG) cells and / or a population of midbrain dopamine (mDA) cells to the brain of a subject (e.g., treating Parkinson's disease and / or reducing immune responses due to acupuncture wounds during cell transplantation).

The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.

The invention discloses a stem cell spray preparation. The stem cell spray preparation is prepared from a mesenchymal stem cell suspension, albumin, glutathione, resveratrol, poloxamer 188 and normal saline. According to the stem cell spray preparation, albumin and normal saline are added, colloid osmotic pressure and crystal osmotic pressure of cells are maintained, glutathione, resveratrol and poloxamer 188 are added at the same time, mechanical shear force in the mesenchymal stem cell spray resisting process can be enhanced, apoptotic cells are reduced, and the clinical effect of target cells is improved; the method is beneficial to the transformation of a cell transplantation mode in stem cell treatment, simplifies the operation difficulty of clinical stem cell use, and contributes to the clinical popularization of stem cells.

This invention discloses a co-culture immune isolation device after cell transplantation, belonging to the technical field of cell culture devices. The device includes a culture plate with several first cavities inside and placement slots outside the first cavities. A cover plate is provided above the culture plate, and several second cavities are provided on the cover plate. A sealing ring is provided on the outside of the second cavities, and a liquid inlet mechanism is provided inside the cover plate, connected to the second cavities. This invention uses the above-mentioned co-culture immune isolation device after cell transplantation to achieve co-culture of multiple cells by setting multiple independent first cavities, preventing cell migration or direct contact and avoiding immune rejection. The protective cover and liquid inlet mechanism achieve closed-loop automatic liquid inlet, continuously diffusing signal molecules into the first cavities to maintain co-culture homeostasis and achieve co-culture of multiple cells.

This invention provides transformed cells for the production of transformed replica pigs for xenotransplantation. [Solution] This invention relates to a transformed replica pig from which the heterologous antigens GGTA1, CMAH, iGb3s, β4GalNT2, and β2M genes have been removed from a PERV Envelope C-negative base, and a method for producing the same. The transformed replica pig according to the present invention can overcome hyperacute and antigen-antibody-mediated immune rejection reactions and T-cell-mediated immune rejection reactions without causing the transfer of porcine endogenous retroviruses that occur in xenologous organ transplantation, and can be usefully utilized as a donor animal for interspecies organ and cell transplantation.

Provided herein are lung forming progenitor cell therapies which do not require pre-conditioning treatments. Administration of the progenitor cells can replace or replenish populations of host-derived patch forming cells to reverse or inhibit fibrosis, promote healing, and improve lung function. Further disclosed herein are methods for monitoring fibrosis, and for determining whether a subject will be receptive to progenitor cell treatments.

The present invention relates to a composition for promoting the osteogenic differentiation efficiency of adipose-derived stem cells. The present invention has revealed that treating Adipose-Derived Stem Cells (ADSCs) from older donors with reduced differentiation efficiency with FGF2 and / or HGF during the early stages of differentiation can restore damaged paracrine function and maximize differentiation efficiency. Therefore, it can be utilized as an in vitro process technology for promoting stem cell differentiation efficiency before or during adipose-derived stem cell transplantation.

The application belongs to the technical field of genetic engineering and cell modification, and discloses a genetic engineering construction method and application of an anti-aging human mesenchymal stem cell. Based on eliminating R-loop formed in the process of cell aging from the source, relieving the adverse effects of genome instability caused by R-loop, the application develops RNH1 overexpression virus transfection MSC aiming at eliminating cell R-loop. The RNH1 overexpression MSC provided by the application exhibits significant anti-aging activity, has strong environmental adaptability and excellent safety characteristics, can effectively resist harsh in-vivo inflammation and aging microenvironment, and avoid the tumorigenic risk after cell transplantation, and the MSCs with stable anti-aging ability can be applied to significantly improve the curative effect of MSCs infusion in-vivo disease treatment.

The present invention relates to a matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, a ferroportin blocker, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of the following: systemic iron levels, transferrin saturation (Tsat), non-transferrin-bound iron (NTBI), and unstable plasma iron (LPI). This may occur by inhibiting the expression of a target gene, where the target gene may be a transmembrane protease, serine 6 (TMPRSS6). Furthermore, the present invention relates to compositions comprising the above compounds, and methods of using such compounds and / or compositions. Such use may include therapeutic use, for example, to reduce iron overload and prevent iron-related toxicity, before, during, or after chemotherapy pretreatment, stem cell transplantation, and engraftment.

This method for estimating the therapeutic effect of stem cell transplantation comprises: a step (S11) for acquiring a plurality of cell images in which a stem cell group in culture is imaged at a plurality of predetermined time points within a cell culturing period for stem cell transplantation for regenerative medicine purposes; a step (S12) for identifying stem cell regions respectively in the plurality of cell images; a step (S13) for acquiring, on the basis of the identified stem cell regions, a plurality of types of index values associated with the stem cell group with respect to each of the plurality of cell images; and a step (S14) for estimating, before the transplantation of the stem cell group obtained by the cell culturing, the therapeutic effect of the transplantation of the stem cell group on the basis of the acquired plurality of types of index values. The plurality of types of index values acquired in step (S13) include a plurality of types of index values associated with the morphologies of the stem cells.

The invention discloses a combined cell transplantation system for Huntington's disease treatment, a preparation method and application. The invention belongs to the technical field of biomedicine, and aims at solving the problems that when an existing stem cell transplantation technology is used for treating the Huntington's disease (HD), the graft survival rate is low, differentiation uncertainty is high, and integration with a host neural network is difficult. The combined cell transplantation system for treating the Huntington's disease comprises human umbilical cord mesenchymal stromal cells (hUC-MSCs) and striatum organoid (hStrOs), the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support, and the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support; the striatum organ takes medium spinous projective neurons (MSNs) for expressing DARPP-32 and CTIP-2 as a main body, and undertakes a cell replacement function. The HD cell therapy is promoted to be converted from a traditional single cell replacement mode to an'immune regulation-nerve regeneration 'multi-dimensional functional remodeling mode through cooperation of the HD cell therapy and the Huntington's disease, and a new way is provided for cell therapy of the Huntington's disease.

The utility model discloses an autologous fat component separation filler, and relates to the technical field of fat filling. Comprising a main body, the main body is composed of a push-injection cylinder and a filling cylinder, the lower inner wall of the push-injection cylinder is fixedly sleeved with a sealing plate, one end, away from the sealing plate, of the push-injection cylinder is rotatably provided with a push-injection knob, the surface of the push-injection knob is sleeved with a lead screw in a penetrating and threaded mode, and a push rod is fixedly installed at the end of the lead screw and slides at the bottom of the sealing plate in a limited mode; a piston head is fixedly installed at the end, away from the lead screw, of the push rod and sleeved with the inner wall of the filling cylinder. The push injection knob is rotated to drive the screw rod in threaded engagement with the push injection knob to move up and down, and in the process, the sliding groove slidably sleeves the surface of the convex block to play a limiting role, so that the piston head makes piston motion on the inner wall of the filling cylinder, constant-speed separation and filling of autologous fat are achieved, and the filling speed can be accurately controlled; therefore, the survival rate of fat cell transplantation is improved.

The invention provides a composition containing neural stem cells, which comprises the following components in parts by mass: 15-20 parts of neural stem cells which are subjected to hypoxia pretreatment and chemical protective agent treatment; 30 to 40 parts of a collagen-sodium alginate composite carrier; 5-8 parts of compound active factors, wherein the compound active factors comprise endostatin, recombinant human epidermal growth factors and superoxide dismutase; and 100 parts of cell protection liquid, wherein the cell protection liquid comprises thioredoxin and nicotinamide. The composition is used for preparing a medicine for treating retina degenerative diseases, and the medicine is an intravitreal injection preparation. The composition synchronously overcomes the three technical bottlenecks of low cell transplantation survival rate, out-of-control differentiation direction and neural network reconstruction disorder through neural stem cell hypoxia pretreatment, active factor compound network, collagen-sodium alginate carrier mechanical adaptation and multi-channel synergistic intervention of a redox protection system.

Provided herein is a lung-forming progenitor cell therapy that does not require preconditioning treatment. Administration of the progenitor cells can replace or replenish a population of host-derived patch-forming cells to reverse or suppress fibrosis, promote healing, and improve lung function. Also disclosed herein are methods for monitoring fibrosis and determining whether a subject is susceptible to progenitor cell therapy.

The invention provides methods of irradiating PSC-derived islet-like clusters with low-dose X- ray; irradiated PSC-derived islet-like clusters for cell therapy with improved safety profile and / or reduced proliferative off-target cells; and irradiated PSC-derived islet-like clusters and cell transplants for use in treatment.

The present disclosure discloses a technical method for treating vitiligo through hair follicle melanocyte stem cell transplantation. The technical method comprises the following steps: extraction of hair follicles; separation of hair follicles; in-vitro culture of hair follicle melanocyte stem cells; inactivation of hair follicles; and transplantation of hair follicle melanocyte stem cells. According to the present disclosure, outer root sheaths of hair follicles containing the hair follicle melanocyte stem cells are obtained through a precise extraction and separation method. Through in-vitro separation and culture and inactivation of hair follicles, a situation that vitiligo only turns black without hairs after surgery is achieved. Through precise transplantation, the original color of the punctate multi-hair follicle orifice can be restored, thereby achieving the purpose of rapidly removing white patches.

The invention discloses a cardiac function preparation as well as a preparation method and application thereof, and belongs to the technical field of preparation of cardiac muscle repair stem cell preparations. Performing mixed culture on endothelial progenitor cells and a heart extracellular matrix to obtain composite cell spheres; carrying out mixed culture on the myocardial-like cell sheet and the composite cell spheres, and after the composite cell spheres are uniformly distributed on the cell sheet and are in a fusion trend, cutting the composite cell spheres into pieces to obtain cell sheet-cell sphere composite particles; and uniformly mixing the composite particles with a poloxamer P407 solution to obtain the heart function preparation. Wherein the endothelial progenitor cells are combined with the cardiac extracellular matrix for use, so that angiogenesis in cardiac tissues can be effectively promoted, cell spheres and myocardial-like cell patches are compounded and cut into pieces, and the pieces can be better adhered to myocardial infarction positions for targeted repair. Experiments prove that the cardiac function preparation can effectively promote angiogenesis of cardiac tissue and myocardial infarction tissue repair, and the problem that the repair function is limited due to the fact that the number of survival cells is insufficient after cell transplantation in a stem cell therapy is solved.

The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.

Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell.

In various embodiments, the present disclosure provides non-human animals comprising human immune cell transplantation and / or a functional human immune system. In various embodiments, the disclosure also provides methods of making the non-human animal. In various embodiments, the disclosure also provides methods of determining the immunogenicity of an antigen or an immunogenic fragment thereof or an antigen therapy and / or identifying an agent that modulates an immune response.

The present invention relates to a process for preparation of compositions comprising human umbilical cord blood plasma and a designed specific culture medium to grow these cells in specific conditions.The compositions of the present invention are rich in regenerative factors derived from mesenchymal stem cells and together with other designed culture medium factors and processes, are useful in tissue regeneration processes and for preservation, conservation and expansion of mesenchymal stem cells. In fact, the present invention allows a better therapeutic option compared to traditional cell transplantation, as it can benefit from the local tissue response to the secreted molecules without the difficulties and complications associated to the engraftment of the allo- or xeno-transplanted mesenchymal stem cells.Therefore, the present invention is in the field of cell-based therapies for skeletal disorders, such as joint disorders, disorders of connective tissue, bone diseases, osteoporosis, and other damaged tissues, and for modulating the inflammatory process related to tissue regeneration as well.

The invention relates to cell biology and regenerative medicine, specifically to a culture method and application for porcine limbal epithelial stem cells. The method involves pretreatment of cells, coating of culture dishes, centrifugation, culturing, passaging, and identification by immunofluorescence staining. The cultured cells are applicable in repairing corneal diseases, including limbal stem cell deficiency. During repair, the cells can be combined with biological materials to form a stem cell engineering carrier for implantation at the injury site. The separation and culture method is simple, yields a large number of cells, and is suitable for use with porcine eyeballs. Limbal epithelial stem cells cultured in vitro form distinct cell clusters, referred to as stem cell islands. The obtained cells exhibit phenotypes including BMI1+, ΔNp63α+, CK14+, and ABCG2+. Based on experimental and clinical research, this method provides a promising approach for cell transplantation in ocular surface reconstruction.

The utility model relates to the technical field of medical care, and discloses a disposable oral mucosa cleaning appliance for stem cell transplantation patients, which comprises a storage box, a storage opening is arranged at the front end of the storage box, two door plates are symmetrically hinged and mounted at the storage opening of the storage box, a horizontally arranged horizontal partition plate is fixedly mounted in the storage opening, and the horizontal partition plate is connected with the storage box. Five sockets are fixedly installed at the upper end and the lower end of the horizontal partition plate at equal intervals, and two first cleaning mechanisms, two second cleaning mechanisms and six third cleaning mechanisms are installed on the ten sockets correspondingly. The portable oral cavity cleaner is convenient to carry and use, a user can clean the oral cavity at any time, and the use is simple and easy to learn.

The object of the present invention is to provide a decellularized graft which is easily manufactured.The problem can be solved by a decellularized cell aggregate, wherein a cultured cell aggregate is decellularized, and surface pores with pore diameter of 5 μm or more are 3 to 45 per 11088 μm2 of aggregate surface, and / or a decellularized cell aggregate, wherein a cultured cell spheroid is decellularized, and lamin of 10 pg / mg or more is contained with respect to the decellularized cell aggregate.

Compositions of recombinant intravenous immunoglobulin (rIVIG) proteins and methods for purifying and using rIVIG proteins. The compositions comprise oligomeric Fc molecules that bind Fc receptors with high avidity. The rIVIG proteins are useful as immunomodulatory molecules to treat immune disorders, including autoimmune diseases, such as refractory immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, lupus, Graves' disease, Kawasaki disease, dermatomyositis, myasthenia gravis, Guillain-Barre syndrome, autoimmune hemolytic anemia, and other immune and inflammatory conditions. The rIVIG proteins are also useful as immunomodulatory agents for patients to reduce immune rejection of organ transplants, stem cell transplants, and bone marrow transplants. In addition, the present invention provides rIVIG proteins of non-human origin for use in veterinary immune disorders, such as canine rIVIG proteins for treating dogs with autoimmune hemolytic anemia, immune thrombocytopenic purpura, rheumatoid arthritis, or other canine immune disorders.

This invention proposes a method and system for prognostic analysis of hematological stem cell transplantation based on OCR and NLP technologies. The method includes receiving and recognizing medical reports uploaded by users, recognizing them as raw text through an OCR service, and then converting them into medical text through post-processing. Subsequently, an NLP service is invoked to extract structured patient features, which are then optimized and input into a prognostic prediction model to obtain prediction results for various prognostic indicators. Finally, the outputs of multiple models are merged to generate a visualized prediction report. This invention achieves seamless data linkage and automated flow between modules without human intervention by constructing a fully automated collaborative architecture that integrates medical data uploading, OCR recognition, structured data extraction, AI prognostic prediction, and result output. This eliminates data breakpoints and human errors, solving the technical problems of isolated functional modules and data flow breakpoints in existing technologies. Furthermore, it improves adaptability to medical scenarios.

The application relates to the technical field of cell biology, and particularly relates to application of a skin organoid conditioned medium in promoting repair of acute skin damage tissue, to a human skin organoid in-vitro model, to collection of a skin organoid conditioned medium (SOCCM) cultured for 6-8 days, enrichment of a variety of secretory factors related to skin repair, inflammation control and angiogenesis in the skin organoid conditioned medium, formation of a characteristic secretome, in-vivo and in-vitro experiment verification that the skin organoid conditioned medium can significantly promote fibroblast migration, vascular endothelial cell lumen formation, accelerate acute skin damage wound closure, promote collagen ordered deposition and tissue remodeling, and improve skin damage repair quality. The application avoids tumorigenic and immunological rejection risks of the organoid / stem cell transplantation, provides a new treatment strategy for repair of the acute skin damage, and can also be applied to repair of chronic non-healing wounds and repair of skin light damage and the like.

The utility model relates to the technical field of stem cell transplantation, in particular to a stem cell transplantation implanter which comprises an injector body, a matching support, a driving assembly and a connecting assembly, the injector body is connected with the matching support, the driving assembly is connected to the matching support, and the connecting assembly is connected to the matching support. According to the utility model, the liquid medicine is uniformly injected through the linear movement of the moving end of the driving assembly along the injector main body, the accurate control of the dosage in the process of injecting the liquid medicine is avoided, and the arranged connecting assembly can be used for quickly connecting and detaching the injector main body and the matched bracket only through rotation; and when the injector main body is mounted and dismounted, the dismounting steps of workers can be reduced.

The purpose of the present invention is to provide a method for reconstructing a degenerated or thinned choroid.　The present invention provides a choroid reconstruction agent containing, as an active ingredient, stem cells that have the ability to differentiate into both blood cells and vascular endothelial cells and that are to be transplanted into a degenerated or thinned choroid.